Bristol-myers Squibb Stock News

Bristol Myers Squibb''s (BMY) phase 3 trial evaluating mavacamten to treat a type of heart condition met its main goal.The company was evaluating mavacamten against placebo in adults…

Why are investors unenthused with the biotech giant's earnings report?

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Cardiomyopathy--BMS Announces Positive Topline Results from Phase 3 VALOR-HCM Trial

Berkshire Hathaway's 13F stock portfolio value increased from ~$293B to ~$331B. BRK.B's largest 3 holdings are 2/3rds of the portfolio. Read the full list here.

Bristol-Myers Squibb Co. (BMY) shares closed today at 1.2% below its 52 week high of $68.59, giving the company a market cap of $145B. The stock is currently up 8.1% year-to-date, up 15.0% over the past 12 months, and up 42.6% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 1.8%. Trading Activity Trading volume this week was 4.2% higher than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.3. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -317.0% The company's stock price performance over the past 12 months beats the peer average by 11.5% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -67.7% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Bristol-Myers Squibb (BMY) priced a public offering of senior unsecured notes in a combined principal amount of $6B.The notes will be issued in four tranche - $1.75B in principal amount…

Bristol-Myers Squibb began 22 separate offers to buy for cash notes issued by the offerors for total purchase price of up to $4B.In the 2025 Pool, offers to buy for cash up to…

Investors wonder which is the top stock to buy if the market crashes? View why we believe Microsoft is the top choice due to financials and dramatic growth in earnings.

Bristol Myers Squibb Co (NYSE: BMY ) and Exelixis Inc (NASDAQ: EXEL ) announced two-year follow-up results from the Phase 3 CheckMate -9ER trial of Opdivo (nivolumab) and Cabometyx (cabozantinib) versus sunitinib in the first-line treatment of advanced renal cell carcinoma. The updated results will be featured at the American Society of Clinical Oncology (ASCO) 2022 Genitourinary Cancers Symposium. With a median follow-up of 32.9 months, … Full story available on Benzinga.com

Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway ( BRK.A , Financial) ( BRK.B , Financial) published its fourth-quarter 13F on Monday.

Global pharmaceutical spending is positioned to keep growing. These three companies can profit from the trend.

Which ETFs Should Investors Be Watching Now? Our Favorite Is The IBB

Bristol Myers Squibb Co (NYSE: BMY) and Exelixis Inc (NASDAQ: EXEL) announced two-year follow-up results from the Phase 3 CheckMate -9ER trial of Opdivo (nivolumab) and Cabometyx (cabozantinib) v

It's worth a look to see what Michael Burry is buying. Click here for my take on the IMPX SPAC that's taking Harley-Davidson's electric bike division public.

Sarat Sethi, DCLA managing partner, joins 'Power Lunch' to deliver this week's edition of 'Buy This, Sell That,' where Sethi explores companies he's interested in buying and those he isn't as inflatio